67656-30-8

Basic information

• Product Name: 4-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
• Synonyms: 10-HYDROXY CAMPTOTHECINE;4-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;10-Hydroxycamptothecin;(4S)-4-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(4S)-4α-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(4S)-4α-Ethyl-4,10-dihydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione;Hydroxycampothecin;1H-Pyrano(3',4':6,7)indolizino(1,2-B)quinoline-3,14(4H,12H)-dione, 4-ethyl-4,10-dihydroxy-, (S)-
• CAS NO: 67656-30-8
• Molecular Formula: C₂₀H₁₆N₂O₅
• Molecular Weight: 364.35
• EINECS: 2017-001-1
• Product Categories: Herb extract;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract
• Mol File: 67656-30-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 224 °C
• Boiling Point: 875.3 °C at 760 mmHg
• Flash Point: 483.2 °C
• Appearance: /
• Density: 1.57 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.743
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.57±0.40(Predicted)
• CAS DataBase Reference: 4-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione(67656-30-8)
• EPA Substance Registry System: 4-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione(67656-30-8)

Safety Data

• Hazardous Substances Data: 67656-30-8(Hazardous Substances Data)

Usage

General Description

4-Ethyl-4,10-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione is a complex organic compound with a molecular formula of C21H13N2O5. It belongs to the class of organic compounds known as quinoline and derivatives, which are characterized by a structure that combines a benzene ring and a pyridine ring. The exact properties, uses, and potential health effects of this particular chemical are not well-documented, requiring further research for a complete understanding. However, given the classification, it could have potential applications in medical and pharmaceutical industries. The compound's structure suggests potential bioactive properties, including possible anticancer or antimicrobial activity, similar to other chemicals in the quinoline class.

InChI:InChI=1/C20H16N2O5/c1-2-20(26)13-7-15-17-10(6-11-14(21-17)4-3-5-16(11)23)8-22(15)18(24)12(13)9-27-19(20)25/h3-7,21,26H,2,8-9H2,1H3/t20-/m0/s1

Upstream product

• 39026-92-1 9-methoxycamptothecin 
• 86639-48-7 Camptothecin 1-oxide 
• 130133-53-8 2-amino-6-nitrobenzaldehyde 
• 606-31-5 2,6-dinitrobenzaldehyde 
• 7689-03-4 camptothecin 
• 91421-42-0 rubitecan 
• 91421-43-1 9-amino-20(S)-camptothecin 
• 110351-94-5 (4S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione 
• 151585-77-2 2,6-dinitrobenzaldehyde ethylene acetal 
• 151585-78-3 2-amino-6-nitrobenzaldehyde ethylene acetal 

Downstream Products

• 39026-92-1 9-methoxycamptothecin 

Relevant articles and documents

Preparation of 9-fluorocamptothecin derivative and application of 9-fluorocamptothecin derivative in antitumor aspect

The invention relates to preparation of 9-fluorocamptothecin compounds and application of the 9-fluorocamptothecin compounds in antitumor drugs. The structural formula of the compounds is shown in the specification. In-vitro antitumor activity screening results show that the compounds 9-fluorocamptothecin I and 7-ethyl-9-fluorocamptothecin II have broad-spectrum antitumor activity and have relatively strong inhibitory activity on cell lines of human liver cancer (HepG2), human ovarian cancer (A2780), human breast cancer (MCF7), human colon cancer (SW480) and human pancreatic cancer (SW1990), and IC50 values of the compounds 9-fluorocamptothecin I and 7-ethyl-9-fluorocamptothecin II are 0.10-0.77 mu M and 0.13-0.25 mu M respectively; particularly, the 7-ethyl-9-fluorocamptothecin II has a relatively strong inhibition effect on human ovarian cancer (A2780) cell lines and human colon cancer (SW480) cell lines, the IC50 of the 7-ethyl-9-fluorocamptothecin II on the human ovarian cancer (A2780) cell lines is 0.074 mu M, andthe IC50 of the 7-ethyl-9-fluorocamptothecin II on the human colon cancer (SW480) cell lines is 0.013 mu M , so that the 7-ethyl-9-fluorocamptothecin II is obviously superior to that of a control drug topotecan. Therefore, the 9-fluorocamptothecin compound is expected to be developed into a novel antitumor drug.

Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers

Four carbon-11-labeled camptothecin derivatives, 9-[11C]methoxy- 20(S)-camptothecin ([11C]5), 10-[11C]methoxy-20(S)- camptothecin ([11C]7), 9-nitro-10-[11C]methoxy-20(S)- camptothecin ([11C]9), and 9-[([11C]trimethylamino)methyl] -10-hydroxy-20(S)-camptothecin ([11C]11), have been synthesized as potential positron emission tomography tracers for imaging of topoisomerase I in cancers.

Process for the preparation of certain 9-substituted camptothecins

A process for the preparation of water soluble camptothecin analogs, including methods for the preparation of intermediates thereof, and the compounds prepared by said process. Water soluble camptothecin analogs are prepared which may be used for inhibiting the growth of tumor cells sensitive to such analogs.